Sato Pharmaceutical Co. Ltd. and Eisai Co. Ltd., both of Tokyo, will co-promote BFE-1224 (fosravuconazole), a triazole class oral antifungal agent, in Japan. Sato will distribute the drug, while both companies will promote the drug. Eisai licensed BFE-1224 to Seren Pharmaceuticals Inc., of Tokyo, in 2010, which subsequently established a co-development agreement with Sato in 2014. Read More
PERTH, Australia – Australian biotech Propanc Biopharma Inc. is advancing its lead product, PRP, toward the clinic in ovarian and pancreatic cancers. The Melbourne-based company reported that recent studies show that the once-daily intravenous combo of pancreatic proenzymes trypsinogen and chymotrypsinogen reduced epithelial to mesenchymal transition (EMT) markers, which not only reverses the EMT process, thereby stopping tumor progression and metastasis, but also represses the development of cancer stem cells. Read More
SUZHOU, China – "It is not enough to try to understand the molecular system behind the disease. You have to understand the importance of each partner in that pathway and pick the right pathway." Read More
Erythropoietin (EPO)-producing cells derived from human induced pluripotent stem (iPS) cells have been shown for the first time to be capable of successfully treating renal anemia in mice, Japanese researchers reported in the Sept. 27, 2017, edition of Science Translational Medicine. Read More
HONG KONG Abbvie Inc. has added a biologics manufacturing unit in its Singapore plant, to ensure sufficient supply of biomedicines and perfect the ecosystem of biologics innovation in the region. Read More
A new Indian study showing that selectively targeting signal-regulating proteins with intrabodies provides a novel means of fine-tuning G protein-coupled receptor (GPCR) functions has important implications for new drug development. Read More
Given the differences in disease patterns and medical practices in a country as large and diverse as India, pharmacovigilance can be quite a challenge. Read More
HONG KONG – China's State Council released a set of guidelines for innovation in new drug and medical device development. The new regulations round up some recent regulatory updates, providing substantial and practical guidance to further push the innovation in China's health care industry. Read More
